Host–microbial co-metabolites: from biogenesis to immunomodulation and implications for health and disease
-
By
-
Ying Wang
-
Liangliang Zhao
-
Ying Zou
-
Lili Nie
-
July 3, 2026
-
Clinical Scorecard: Co-metabolites from Host and Microbiota: Their Formation, Role in Immune Modulation, and Impact on Health and Disease
At a Glance
| Category | Detail |
|---|
| Condition | Host–microbial co-metabolites |
| Key Mechanisms | Involves biochemical collaboration between gut microbiota and host enzymes, influencing immune modulation and metabolic regulation. |
| Target Population | Individuals with dysbiosis or chronic inflammatory conditions. |
| Care Setting | Clinical research and metabolic health assessment. |
Key Highlights
- Co-metabolites are generated through host-microbe enzymatic interactions.
- Dysregulation of co-metabolites is linked to chronic inflammation and various diseases.
- Key co-metabolites include TMAO, indoxyl sulfate, and secondary bile acids.
Guideline-Based Recommendations
Diagnosis
- Assess gut microbiota composition and co-metabolite levels in patients with chronic diseases.
Management
- Consider interventions targeting gut microbiota to restore co-metabolite balance.
Monitoring & Follow-up
- Regularly evaluate levels of key co-metabolites in patients with metabolic disorders.
Risks
- Monitor for chronic low-grade inflammation associated with dysregulated co-metabolite levels.
Patient & Prescribing Data
Patients with inflammatory bowel disease, metabolic disorders, cardiovascular disease, and other chronic conditions.
Therapeutic strategies may involve modulation of gut microbiota to influence co-metabolite production.
Clinical Best Practices
- Integrate microbiome analysis in the assessment of chronic diseases.
- Utilize dietary and pharmacological approaches to modify gut microbiota.
Related Resources & Content
